 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | zampilimab (UCB7858) / UCB
Preclinical, Journal: The effect of TG2-inhibitory monoclonal antibody zampilimab on tissue fibrosis in human in vitro and primate in vivo models of chronic kidney disease. (Pubmed Central) - May 16, 2024
Weekly intravenous administration of zampilimab in cynomolgus monkeys with unilateral ureteral obstruction reduced fibrosis at 4 weeks by >50%, with no safety signals. Our data support the clinical investigation of zampilimab for the treatment of kidney fibrosis.
- | zampilimab (UCB7858) / UCB
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury (clinicaltrials.gov) - Sep 21, 2022
P1/2, N=3, Terminated, Sponsor: UCB Biopharma SRL
Our data support the clinical investigation of zampilimab for the treatment of kidney fibrosis. N=12 --> 3 | Trial completion date: May 2025 --> May 2022 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> May 2022; Recruitment challenges
- ||| zampilimab (UCB7858) / UCB
Enrollment change, Trial completion date, Trial primary completion date: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury (clinicaltrials.gov) - Oct 11, 2021
P1/2, N=12, Recruiting, Sponsor: UCB Biopharma SRL
N=12 --> 3 | Trial completion date: May 2025 --> May 2022 | Recruiting --> Terminated | Trial primary completion date: May 2025 --> May 2022; Recruitment challenges N=177 --> 12 | Trial completion date: Oct 2023 --> May 2025 | Trial primary completion date: Oct 2023 --> May 2025
- || zampilimab (UCB7858) / UCB
Trial completion: A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants (clinicaltrials.gov) - Aug 5, 2021
P1, N=16, Completed, Sponsor: UCB Biopharma SRL
N=177 --> 12 | Trial completion date: Oct 2023 --> May 2025 | Trial primary completion date: Oct 2023 --> May 2025 Active, not recruiting --> Completed
- || zampilimab (UCB7858) / UCB
Enrollment closed: A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants (clinicaltrials.gov) - Apr 18, 2021
P1, N=16, Active, not recruiting, Sponsor: UCB Biopharma SRL
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || zampilimab (UCB7858) / UCB
Enrollment open: A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants (clinicaltrials.gov) - Jan 26, 2021
P1, N=16, Recruiting, Sponsor: UCB Biopharma SRL
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || zampilimab (UCB7858) / UCB
New P1 trial: A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants (clinicaltrials.gov) - Jan 11, 2021
P1, N=16, Not yet recruiting, Sponsor: UCB Biopharma SRL
- zampilimab (UCB7858) / UCB
[VIRTUAL] Using Skin Biopsies to Measure Target Occupancy of a Renal Antifibrotic Monoclonal Antibody (mAb) in a Phase 1 Clinical Study (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_2825;
P1, P1/2
A Phase 1/2 study of zampilimab in patients with post-renal transplant fibrosis is ongoing (NCT04335578). Funding: Commercial Support
- zampilimab (UCB7858) / UCB
[VIRTUAL] Development of a CKD Model in Cynomolgus Monkeys and Its Application to Test Zampilimab, a Monoclonal Antibody (mAb) Specific for Human Transglutaminase 2 (TG2) (On-Demand) - Oct 11, 2020 - Abstract #KIDNEYWEEK2020KIDNEY_WEEK_1181;
P1/2
A Phase 1/2 study of zampilimab for the treatment of post-renal transplant fibrosis is ongoing (NCT04335578). Funding: Commercial Support
- || zampilimab (UCB7858) / UCB
Trial completion date, Trial primary completion date: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury (clinicaltrials.gov) - Sep 28, 2020
P1/2, N=177, Recruiting, Sponsor: UCB Biopharma SRL
Funding: Commercial Support Trial completion date: Jul 2023 --> Nov 2023 | Trial primary completion date: Jul 2023 --> Nov 2023
- ||| zampilimab (UCB7858) / UCB
Enrollment open: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury (clinicaltrials.gov) - Jun 25, 2020
P1/2, N=177, Recruiting, Sponsor: UCB Biopharma SRL
Trial completion date: Jul 2023 --> Nov 2023 | Trial primary completion date: Jul 2023 --> Nov 2023 Suspended --> Recruiting
- zampilimab (UCB7858) / UCB
Trial suspension: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury (clinicaltrials.gov) - Apr 19, 2020
P1/2, N=1, Suspended, Sponsor: UCB Biopharma SRL
Suspended --> Recruiting Active, not recruiting --> Suspended
- zampilimab (UCB7858) / UCB
New P1/2 trial: A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury (clinicaltrials.gov) - Apr 5, 2020
P1/2, N=1, Active, not recruiting, Sponsor: UCB Biopharma SRL
- ||| zampilimab (UCB7858) / UCB
Trial completion, Trial completion date, Trial primary completion date: A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers (clinicaltrials.gov) - Feb 8, 2018
P1, N=78, Completed, Sponsor: UCB Biopharma S.P.R.L.
Active, not recruiting --> Suspended Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018 | Trial primary completion date: Jan 2018 --> Jan 2018
- || zampilimab (UCB7858) / UCB
Enrollment closed, Trial primary completion date: A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers (clinicaltrials.gov) - Sep 12, 2017
P1, N=80, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Active, not recruiting --> Completed | Trial completion date: Jan 2018 --> Jan 2018 | Trial primary completion date: Jan 2018 --> Jan 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Jan 2018
- ||| zampilimab (UCB7858) / UCB
New P1 trial: A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers (clinicaltrials.gov) - Aug 25, 2016
P1, N=80, Recruiting, Sponsor: UCB Biopharma S.P.R.L.